Literature DB >> 3474632

Characterization of a preleukemic state induced by Moloney murine leukemia virus: evidence for two infection events during leukemogenesis.

B R Davis, B K Brightman, K G Chandy, H Fan.   

Abstract

A preleukemic state in mice inoculated with Moloney murine leukemia virus (Mo-MuLV) was characterized. Six to 10 weeks after neonatal inoculation, animals developed mild splenomegaly and generalized hematopoietic hyperplasia. The hyperplasia was evident from myeloid and erythroid progenitor assays. A nonleukemogenic variant, Mo+PyF101 Mo-MuLV, did not induce the hyperplasia; this suggests that the hyperplasia is a necessary event in Mo-MuLV leukemogenesis. Another variant, MF-MuLV, which contains the long terminal repeat of Friend MuLV and causes erythroid leukemia instead of T-cell lymphoma, also induced the preleukemic hyperplasia. A model for Mo-MuLV leukemogenesis is presented in which two infection events are necessary: the first leads to generalized hematopoietic hyperplasia, and the second results in site-specific insertion and long terminal repeat activation of cellular protooncogenes.

Entities:  

Mesh:

Year:  1987        PMID: 3474632      PMCID: PMC305208          DOI: 10.1073/pnas.84.14.4875

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  23 in total

1.  Properties of "mink cell focus-inducing" (MCF) virus isolated from spontaneous lymphoma lines of BALB/c mice carrying Moloney leukemia virus as an endogenous virus.

Authors:  M Vogt
Journal:  Virology       Date:  1979-02       Impact factor: 3.616

2.  Characteristics of preleukemia cells induced in mice.

Authors:  N Haran-Ghera; N Rubio; F Leef; G Goldstein
Journal:  Cell Immunol       Date:  1978-05       Impact factor: 4.868

Review 3.  The immune response to C-type viruses and its potential role in leukemogenesis.

Authors:  J N Ihle; L Enjuanes; J C Lee; J Keller
Journal:  Curr Top Microbiol Immunol       Date:  1982       Impact factor: 4.291

4.  Plaque assay techniques for murine leukemia viruses.

Authors:  W P Rowe; W E Pugh; J W Hartley
Journal:  Virology       Date:  1970-12       Impact factor: 3.616

5.  M-MuLV-induced leukemogenesis: integration and structure of recombinant proviruses in tumors.

Authors:  H van der Putten; W Quint; J van Raaij; E R Maandag; I M Verma; A Berns
Journal:  Cell       Date:  1981-06       Impact factor: 41.582

6.  Proviral integration site Mis-1 in rat thymomas corresponds to the pvt-1 translocation breakpoint in murine plasmacytomas.

Authors:  L Villeneuve; E Rassart; P Jolicoeur; M Graham; J M Adams
Journal:  Mol Cell Biol       Date:  1986-05       Impact factor: 4.272

7.  Potential leukemic cells among bone marrow cells of young AKR/J mice.

Authors:  N Haran-Ghera
Journal:  Proc Natl Acad Sci U S A       Date:  1980-05       Impact factor: 11.205

8.  Role for the 3' end of the genome in determining disease specificity of Friend and Moloney murine leukemia viruses.

Authors:  P A Chatis; C A Holland; J W Hartley; W P Rowe; N Hopkins
Journal:  Proc Natl Acad Sci U S A       Date:  1983-07       Impact factor: 11.205

9.  A common region for proviral DNA integration in MoMuLV-induced rat thymic lymphomas.

Authors:  P N Tsichlis; P G Strauss; L F Hu
Journal:  Nature       Date:  1983 Mar 31-Apr 6       Impact factor: 49.962

10.  Effects of murine leukemia virus infection on long-term hematopoiesis in vitro emphasized by increased survival of bone marrow cultures derived from BALB/Mo mice.

Authors:  J S Greenberger; R K Shadduck; R Jaenisch; A Waheed; M A Sakakeeny
Journal:  Cancer Res       Date:  1981-09       Impact factor: 12.701

View more
  37 in total

1.  Appearance of mink cell focus-inducing recombinants during in vivo infection by moloney murine leukemia virus (M-MuLV) or the Mo+PyF101 M-MuLV enhancer variant: implications for sites of generation and roles in leukemogenesis.

Authors:  J K Lander; B Chesebro; H Fan
Journal:  J Virol       Date:  1999-07       Impact factor: 5.103

2.  Disruption of hematopoiesis and thymopoiesis in the early premalignant stages of infection with SL3-3 murine leukemia virus.

Authors:  Karen Rulli; Jack Lenz; Laura S Levy
Journal:  J Virol       Date:  2002-03       Impact factor: 5.103

3.  Moloney murine leukemia virus-induced tumors show altered levels of proapoptotic and antiapoptotic proteins.

Authors:  C Bonzon; H Fan
Journal:  J Virol       Date:  2000-09       Impact factor: 5.103

4.  Bone marrow depletion by 89Sr complements a preleukemic defect in a long terminal repeat variant of Moloney murine leukemia virus.

Authors:  Q X Li; H Fan
Journal:  J Virol       Date:  1991-08       Impact factor: 5.103

5.  Diminished potential for B-lymphoid differentiation after murine leukemia virus infection in vivo and in EML hematopoietic progenitor cells.

Authors:  Samantha L Finstad; Naomi Rosenberg; Laura S Levy
Journal:  J Virol       Date:  2007-04-11       Impact factor: 5.103

6.  A nonstructural gag-encoded glycoprotein precursor is necessary for efficient spreading and pathogenesis of murine leukemia viruses.

Authors:  A Corbin; A C Prats; J L Darlix; M Sitbon
Journal:  J Virol       Date:  1994-06       Impact factor: 5.103

7.  Replacement of interleukin-2 (IL-2)-generated mitogenic signals by a mink cell focus-forming (MCF) or xenotropic virus-induced IL-9-dependent autocrine loop: implications for MCF virus-induced leukemogenesis.

Authors:  M M Flubacher; S E Bear; P N Tsichlis
Journal:  J Virol       Date:  1994-12       Impact factor: 5.103

8.  Increased hematopoiesis in mice soon after infection by Friend murine leukemia virus.

Authors:  T Mitchell
Journal:  J Virol       Date:  1993-06       Impact factor: 5.103

9.  A multistep process of leukemogenesis in Moloney murine leukemia virus-infected mice that is modulated by retroviral pseudotyping and interference.

Authors:  M Lavignon; L Evans
Journal:  J Virol       Date:  1996-06       Impact factor: 5.103

10.  Moloney murine leukemia virus activates NF-kappa B.

Authors:  J Pak; D V Faller
Journal:  J Virol       Date:  1996-06       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.